Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Fowler

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
The Pediatric Infectious Disease Journal|June 5, 1998
The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study GroupJ S Read, C E Frasch, K Rich, et al.
Journal of Behavioral Medicine|June 1, 1994
Evaluation of a home-based intervention program to reduce infant passive smoking and lower respiratory illnessR A Greenberg, V J Strecher, K E Bauman, et al.
The Journal of Infectious Diseases|May 1, 1997
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 TeamS S Bakshi, P Britto, E Capparelli, et al.
The New England Journal of Medicine|June 12, 1997
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 TeamJ A Englund, C J Baker, C Raskino, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 4, 1999
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudineI C Hanson, T A Antonelli, R S Sperling, et al.
The New England Journal of Medicine|August 5, 1999
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 TeamL M Mofenson, J S Lambert, E R Stiehm, et al.
AIDS (London, England)|March 15, 2000
HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study GroupS L Welles, J Pitt, R Colgrove, et al.
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
AIDS (London, England)|April 10, 1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)P Musoke, L A Guay, D Bagenda, et al.
Lancet (London, England)|September 15, 1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialL A Guay, P Musoke, T Fleming, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
The Pediatric Infectious Disease Journal|June 5, 1998
The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study GroupJ S Read, C E Frasch, K Rich, et al.
Journal of Behavioral Medicine|June 1, 1994
Evaluation of a home-based intervention program to reduce infant passive smoking and lower respiratory illnessR A Greenberg, V J Strecher, K E Bauman, et al.
The Journal of Infectious Diseases|May 1, 1997
Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 TeamS S Bakshi, P Britto, E Capparelli, et al.
The New England Journal of Medicine|June 12, 1997
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 TeamJ A Englund, C J Baker, C Raskino, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 4, 1999
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudineI C Hanson, T A Antonelli, R S Sperling, et al.
The New England Journal of Medicine|August 5, 1999
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 TeamL M Mofenson, J S Lambert, E R Stiehm, et al.
AIDS (London, England)|March 15, 2000
HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study GroupS L Welles, J Pitt, R Colgrove, et al.
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
AIDS (London, England)|April 10, 1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)P Musoke, L A Guay, D Bagenda, et al.
Lancet (London, England)|September 15, 1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialL A Guay, P Musoke, T Fleming, et al.
Pageof 7